by Brooks Hays
Cambridge, Mass. (UPI) Jun 20, 2013
A 25-year-old man previously unable to grow hair on his body, now has a full head of hair thanks to a medication for rheumatoid arthritis called tofacitinib citrate.
The young patient suffered from both plaque psoriasis, a condition involving scaly red areas of skin, and alopecia universalis, an autoimmune disease whereby baldness extends across the entirety of the body.
When the man went to Yale Dermatology to be treated for the psoriasis, Dr. Brett A. King suggested the arthritis drug might address both conditions. The patient took 10 milligrams a day, and the results were rather miraculous.
"The results are exactly what we hoped for," said Dr. King, who recently detailed the treatment success in a study published online in the Journal of Investigative Dermatology. "This is a huge step forward in the treatment of patients with this condition. While it's one case, we anticipated the successful treatment of this man based on our current understanding of the disease and the drug. We believe the same results will be duplicated in other patients, and we plan to try."
Previously, the drug has mainly been used to treat types of psoriasis. But the recent study shows its potential in reversing the effects of alopecia. Doctors believe the drug blocked the patient's immune system from attacking his hair follicles.
"By eight months there was full regrowth of hair," said study coauthor Dr. Brittany G. Craiglow. "The patient has reported feeling no side effects, and we've seen no lab test abnormalities, either."
Hospital and Medical News at InternDaily.com
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2014 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement All images and articles appearing on Space Media Network have been edited or digitally altered in some way. Any requests to remove copyright material will be acted upon in a timely and appropriate manner. Any attempt to extort money from Space Media Network will be ignored and reported to Australian Law Enforcement Agencies as a potential case of financial fraud involving the use of a telephonic carriage device or postal service.|